ZEAL — Zealand Pharma A/S Income Statement
0.000.00%
- DKK25.54bn
- DKK17.39bn
- DKK62.69m
Annual income statement for Zealand Pharma A/S, fiscal year end - December 31st, DKK millions except per share, conversion factor applied.
R2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | Interim Report | ARS | ARS | ARS |
Standards: | IFRS | — | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 192 | 109 | 104 | 343 | 62.7 |
Cost of Revenue | |||||
Gross Profit | 192 | 97.6 | 104 | 324 | 54.8 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 818 | 893 | 1,064 | 1,051 | 1,335 |
Operating Profit | -626 | -784 | -960 | -708 | -1,272 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -674 | -759 | -972 | -709 | -1,083 |
Provision for Income Taxes | |||||
Net Income After Taxes | -669 | -755 | -966 | -704 | -1,079 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -847 | -1,018 | -1,202 | -704 | -1,079 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -847 | -1,018 | -1,202 | -704 | -1,079 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -17.4 | -17.6 | -18.3 | -10.8 | -16.2 |
Dividends per Share |